Hanover, NH (Scicasts) — In the first experimental use of algorithms that employ structure-based molecular modelling to optimize deimmunized drug candidates, Dr. Karl Griswold, and co-investigator Dr. Christopher Bailey-Kellogg, of Dartmouth College complement their prior sequence-based deimmunizing algorithms and expand the tool kit of protein engineering technologies to use in next generation drug development. Their paper, "Protein Deimmunization via Structure-based Design Enables Efficient Epitope Deletion at High Mutational Loads," was published in Biotechnology and Bioengineering.
"This work is part of our larger collaborative initiative to develop performance-enhanced protein drugs that are invisible to the human immune system," explained Griswold. "Biotherapeutics offer potent treatment options for a wide range of diseases but, due to their biological origins, these powerful therapies can elicit detrimental immune responses in humans."
Read more on SciCasts